Shares of Cooper Companies, Inc. (The) (NYSE:COO) have received a consensus recommendation of “Buy” from the fourteen research firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $261.11.

A number of equities research analysts recently issued reports on COO shares. Zacks Investment Research lowered Cooper Companies, Inc. (The) from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. KeyCorp reaffirmed a “hold” rating on shares of Cooper Companies, Inc. (The) in a research note on Monday, August 28th. Robert W. Baird reaffirmed a “buy” rating and issued a $267.00 target price (up previously from $251.00) on shares of Cooper Companies, Inc. (The) in a research note on Sunday, September 3rd. BidaskClub lowered Cooper Companies, Inc. (The) from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $272.00 target price on shares of Cooper Companies, Inc. (The) in a research note on Friday, October 13th.

In other Cooper Companies, Inc. (The) news, Director Gary S. Petersmeyer sold 3,977 shares of the business’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $244.94, for a total value of $974,126.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. ProVise Management Group LLC raised its holdings in Cooper Companies, Inc. (The) by 0.6% in the 2nd quarter. ProVise Management Group LLC now owns 1,177 shares of the medical device company’s stock valued at $282,000 after acquiring an additional 7 shares during the last quarter. YorkBridge Wealth Partners LLC raised its holdings in Cooper Companies, Inc. (The) by 2.1% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 531 shares of the medical device company’s stock valued at $126,000 after acquiring an additional 11 shares during the last quarter. Creative Planning raised its holdings in Cooper Companies, Inc. (The) by 0.8% in the 2nd quarter. Creative Planning now owns 1,909 shares of the medical device company’s stock valued at $457,000 after acquiring an additional 16 shares during the last quarter. CIBC Asset Management Inc raised its holdings in Cooper Companies, Inc. (The) by 0.3% in the 2nd quarter. CIBC Asset Management Inc now owns 4,697 shares of the medical device company’s stock valued at $1,125,000 after acquiring an additional 16 shares during the last quarter. Finally, Wedbush Securities Inc. raised its holdings in Cooper Companies, Inc. (The) by 1.0% in the 2nd quarter. Wedbush Securities Inc. now owns 1,783 shares of the medical device company’s stock valued at $427,000 after acquiring an additional 18 shares during the last quarter. Institutional investors own 96.04% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cooper Companies, Inc. (The) (COO) Given Average Recommendation of “Buy” by Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/26/cooper-companies-inc-the-coo-given-average-recommendation-of-buy-by-brokerages.html.

Cooper Companies, Inc. (NYSE COO) traded up 1.06% during midday trading on Thursday, hitting $240.41. The company had a trading volume of 454,779 shares. The stock’s 50-day moving average price is $239.84 and its 200-day moving average price is $232.96. Cooper Companies, Inc. has a 52-week low of $158.73 and a 52-week high of $256.39. The stock has a market cap of $11.77 billion, a PE ratio of 34.48 and a beta of 0.54.

Cooper Companies, Inc. (The) (NYSE:COO) last posted its earnings results on Thursday, August 31st. The medical device company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.58 by $0.06. Cooper Companies, Inc. (The) had a return on equity of 16.00% and a net margin of 16.45%. The firm had revenue of $556.00 million for the quarter, compared to analyst estimates of $552.32 million. During the same quarter in the prior year, the company earned $2.30 EPS. Cooper Companies, Inc. (The)’s revenue was up 8.0% on a year-over-year basis. On average, equities research analysts expect that Cooper Companies, Inc. will post $9.73 EPS for the current fiscal year.

Cooper Companies, Inc. (The) Company Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.